Strategic partnerships SCRI has a track record of high-profile collaborations with major pharma and oncology networks, including Pfizer, Bristol-Myers Squibb, and The US Oncology Network affiliates. This indicates strong partner receptivity and potential for expanded co-development, trial outsourcing, and access to broader patient populations.

Broad enrollment footprint With over 1,300 physicians enrolling patients across 200+ locations in more than 20 states, SCRI offers extensive geographic reach and diverse patient pools, presenting opportunities for multi-site pivotal trials and faster enrollment services for sponsors.

Specialized oncology focus SCRI’s deep emphasis on oncology and experience conducting more than 850 first‑in‑human trials positions it as a preferred partner for early‑phase programs and rapid progression studies, particularly for novel cancer therapies seeking specialized expertise.

Financial scale and stability With revenue in the hundreds of millions and a proven services model, SCRI presents as a financially credible partner capable of handling large trial volumes, complex budgets, and long-term collaborations with pharma companies.

Growth through networks Recent partnerships with regional cancer centers and community networks signal SCRI’s strategy to expand access and enrollment through established communities, suggesting opportunities to jointly scale trials in new markets and leverage local site ecosystems.